Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 10:59 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 3,553 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Fluids Clear all

Conditions: Hypoglycemia
Interventions: Continuous Glucose Monitoring, activity monitor, Mixed meal tolerance test, Glucagon Sensitivity Testing, Hypoglycemic Hyperinsulinemic Clamp, analysis of fecal microbiome; Diagnostic Test
Lead sponsor: Joslin Diabetes Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 105 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Alpha₁-Antitrypsin Deficiency
Interventions: Liquid Alpha₁-PI, Prolastin-C; Biological
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 6
States / cities: Denver, Colorado • Gainesville, Florida • Miami, Florida + 3 more

Conditions: Sepsis
Interventions: LifeFlow Rapid infuser, Push Pull; Device
Lead sponsor: Phoenix Children's Hospital; Other
Eligibility: 1 Year to 19 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Wounded Warrior, Limb Shortening, Amputation
Interventions: Enhanced Fat Grafting, Standard fat graft; Device · Procedure
Lead sponsor: J. Peter Rubin, MD; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Cachexia
Interventions: AV-380, Placebo; Drug
Lead sponsor: AVEO Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Newark, New Jersey

Conditions: Sepsis, Hypotension
Interventions: Treatment Starling SV monitor; Device
Lead sponsor: Cheetah Medical Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 11
States / cities: San Francisco, California • Denver, Colorado • Atlanta, Georgia + 7 more

Conditions: Pancreatic Cyst
Interventions: Not listed
Lead sponsor: Translational Genomics Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: Newport Beach, California • Atlanta, Georgia

Conditions: Healthy Subjects
Interventions: E2027, E2027 matched placebo; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 74 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Glendale, California

Conditions: HIV Infections
Interventions: Bronchoalveolar lavage; Procedure
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2003
U.S. locations: 4
States / cities: Indianapolis, Indiana • New York, New York • Cincinnati, Ohio + 1 more

Conditions: Malignant Small Bowel Obstruction, Malignant Gastric Outlet Obstruction
Interventions: AspireAssist device, Standard decompressive PEG tube, gastric outlet obstruction scoring system (GOOSS) questionnaire, Modified Gastroparesis Cardinal Symptom Index (GCSI) questionnaire, Patient satisfaction and ease of use survey; Device · Other
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Hydrocephalus
Interventions: wireless thermal anisotropy measurement device; Device
Lead sponsor: Rhaeos, Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Chicago, Illinois • Richmond, Virginia

Conditions: Urea Cycle Disorders
Interventions: HPN-100, NaPBA; Drug
Lead sponsor: Amgen; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 7
States / cities: Los Angeles, California • Washington D.C., District of Columbia • New York, New York + 4 more

Conditions: Post-Treatment Lyme Disease
Interventions: Ceftriaxone (Rocephin®), Dextrose 5% (D5W); Drug
Lead sponsor: State University of New York - Upstate Medical University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: East Syracuse, New York

Conditions: Sepsis, Hypotension, Septic Shock
Interventions: NICOM; Device
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 251 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer
Interventions: defined green tea catechin extract, placebo, immunohistochemistry staining method, immunoenzyme technique, questionnaire administration, therapeutic conventional surgery, high performance liquid chromatography, mass spectrometry; Dietary Supplement · Other · Procedure
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 45 Years to 75 Years · Male only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Mantle Cell Lymphoma
Interventions: Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy, Computed Tomography, Positron Emission Tomography, Rituximab, Rituximab and Hyaluronidase Human; Procedure · Biological
Lead sponsor: ECOG-ACRIN Cancer Research Group; Network
Eligibility: 18 Years to 70 Years
Enrollment: 689 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 374
States / cities: Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 236 more

Conditions: Alzheimer Disease
Interventions: GSI-953, Placebo; Drug · Other
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007
U.S. locations: 1
States / cities: Glendale, California

Conditions: Cancer of the Rectum, Neoplasms, Rectal, Rectal Cancer, Rectal Tumors, Rectal Adenocarcinoma
Interventions: Diagnostic Biopsy and Surgical Procedure, Intravoxel incoherent motion MRI (IVIM), Dynamic Contrast Enhanced MRI (DCE-MRI), RNA gene expression analysis; Procedure · Genetic
Lead sponsor: Providence Health & Services; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 2
States / cities: Portland, Oregon

Conditions: Influenza
Interventions: CAIV-T, Liquid; Biological
Lead sponsor: MedImmune LLC; Industry
Eligibility: 6 Months to 18 Months
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2001
U.S. locations: 1
States / cities: Monroe, Wisconsin

Conditions: Smallpox
Interventions: MVA Smallpox Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 38 Years
Enrollment: 523 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 8
States / cities: Decatur, Georgia • Iowa City, Iowa • Baltimore, Maryland + 4 more

Conditions: Diarrhea, Gastroenteritis
Interventions: Zinc Sulfate, Placebo oral capsule; Drug
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 6 Months to 6 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetes Mellitus, Type 2
Interventions: No breakfast/beverage only, Breakfast, 10004RF; Other
Lead sponsor: Abbott Nutrition; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 2
States / cities: Glen Ellyn, Illinois • Cincinnati, Ohio

Conditions: Degenerative Disc Disease, Spondylolisthesis, Spondylosis
Interventions: One or two level lumbar interbody fusion surgery, Nucel; Procedure · Other
Lead sponsor: Organogenesis; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 3
States / cities: Tampa, Florida • Shreveport, Louisiana • Charlotte, North Carolina

Conditions: Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
Interventions: panobinostat, everolimus, laboratory biomarker analysis, pharmacological study, liquid chromatography, mass spectrometry, enzyme-linked immunosorbent assay, immunohistochemistry staining method; Drug · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 2
States / cities: Buffalo, New York • Rochester, New York

Search by objective public record fields.

Mechanisms of Post-Bariatric Hypoglycemia

A Study to Assess Safety and PK of Liquid Alpha₁-Proteinase Inhibitor (Human) in Treating Alpha₁-Antitrypsin Deficiency

LifeFlow Sepsis Study

AMP30: Autologous Fat Grafting, Amputation Sites Pain: Randomized

A Phase 1 Study of AV-380 in Healthy Subjects

Fluid Responsiveness Evaluation in Sepsis-associated Hypotension

Blood and Cystic Fluid From Patients Undergoing Surgery for Worrisome Pancreatic Cysts

A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2027 in Healthy Subjects

Effect of Anti-HIV Therapy (HAART) on HIV Levels in the Lungs and on Lung Cell Inflammation in HIV-Infected Patients

AspireAssist for Palliative Venting Gastrostomy in Malignant Bowel Obstruction Patients

Assessment of CSF Shunt Flow During Activities of Daily Living and Sleep With a Thermal Measurement Device

Study of the Safety and Tolerability of HPN-100 Compared to Sodium Phenylbutyrate in Children With Urea Cycle Disorders

Ceftriaxone Pulse Dose for Post-Treatment Lyme Disease

Non-Invasive Cardiac Output Monitor (NICOM) for Goal-directed Fluid Resuscitation for Inpatients With Hypotension and/or Septic Shock

Defined Green Tea Catechin Extract in Treating Patients With Localized Prostate Cancer Undergoing Surgery

Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission

Study Evaluating GSI-953 in Healthy Young and Alzheimer's Patients

Immunoscore in Rectal Cancer

Trial to Investigate Viral Shedding in Healthy Children Vaccinated With Vaccine Virus Liquid (CAIV-T)

Lyophilized IMVAMUNE® (1x10^8 TCID50) Versus Liquid IMVAMUNE® (1x10^8 TCID50) Administered Subcutaneously and a Lower Dose Liquid IMVAMUNE® (2x10^7 TCID50) Administered Intradermally

Oral Zinc for the Treatment of Acute Diarrhea in US Children

Effect of Nutritional Products on Metabolic Parameters in Subjects With Type 2 Diabetics

Study of Nucel for One and Two Level Lumbar Interbody Fusion

Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate